Drugs.com Clinical Trial ResultsOriginal article
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Phase 2positivediranersenPositive
AI Analysis
Summary
Biogen announced positive Phase 2 CELIA data for diranersen, an antisense oligonucleotide targeting tau, demonstrating meaningful clinical outcomes and robust tau reduction in early Alzheimer's disease patients. The data was presented at the Alzheimer's Association International Conference (AAIC).
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Meaningful clinical outcomes and robust tau reduction demonstrated
Importance:7/10
Sentiment:
0.80
Alzheimer's DiseaseAntisense OligonucleotideTau TargetingAAIC PresentationPhase 2 Data
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 14, 2026 8:07 PM